Department of Colorectal Surgery, Calderdale and Huddersfield NHS Trust, Huddersfield, UK.
Colorectal Dis. 2013 Dec;15(12):1481-8. doi: 10.1111/codi.12325.
The prognosis of anal adenocarcinoma is poor and the management remains controversial. We carried out a literature review to identify current practice in the management of anal adenocarcinoma.
A systematic review of the literature was performed for studies in the English language published between 1950 and 2011. All those that focused on the management of anal adenocarcinoma were considered for inclusion.
Sixteen retrospective observational studies were identified; no randomized trials were found. Most of the studies contained small numbers of patients due to the rarity of anal adenocarcinoma. Treatment included local excision), radiotherapy, chemotherapy, chemoradiotherapy and abdominoperineal excision. Most studies concluded that a multimodality approach, combining radical surgical resection with neoadjuvant/adjuvant chemoradiotherapy was the optimal management strategy.
The prognosis of anal adenocarcinoma is poor, and there is little information on the optimal management. The relevant studies indicate that a combination of radical surgical resection and pre- or postoperative chemoradiotherapy offers the best chance of survival.
肛门腺癌的预后较差,其治疗仍存在争议。我们进行了文献回顾,以确定肛门腺癌治疗的现状。
对 1950 年至 2011 年间发表的英文文献进行了系统的文献回顾。所有关注肛门腺癌治疗的研究都被认为是包含在内的。
确定了 16 项回顾性观察性研究;未发现随机试验。由于肛门腺癌的罕见性,大多数研究的患者数量较少。治疗包括局部切除、放疗、化疗、放化疗和腹会阴切除术。大多数研究的结论是,采用多模式治疗,将根治性手术切除与新辅助/辅助放化疗相结合,是最佳的治疗策略。
肛门腺癌的预后较差,关于最佳治疗方法的信息很少。相关研究表明,根治性手术切除联合术前或术后放化疗可获得最佳生存机会。